RXi Expects to Select Lead Rx Candidate by Year-End, Could Tap Self-Delivering Molecule | GenomeWeb

By Doug Macron

After making a number of changes to its pipeline since it was spun out of CytRx in early 2007, RXi Pharmaceuticals is poised to select its first therapeutic candidate before the end of the year, the company's top official told RNAi News last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.